Associated Papers
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.
de Wit M et al.
Ebiomedicine, 2020
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
28420421 (PubMed )
Supplement: 13073_2017_424_MOESM7_ESM.xlsx › Sheet1
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM et al.
Nature, 2015
25629630 (PubMed )
Supplement: NIHMS645459-supplement-1.pdf
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.
Righi L et al.
Bmc Cancer, 2013
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
He M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Select a paper to view details